Abstract
Heparin-induced thrombocytopenia (HIT) is a wellknown complication after exposure to heparin products. Profound thrombocytopenia has also been reported with the use of abciximab, a glycoprotein IIb/IIIa receptor antagonist, which is used during percutaneous coronary intervention. Acute stent thrombosis is a rare but serious complication of HIT. We report an unusual case of acute stent thrombosis with concomitant heparin- and abciximab-induced profound thrombocytopenia and discuss the subsequent treatment strategies. Prompt identification and management of this disorder is critically important to avoid devastating complications.
MeSH terms
-
Abciximab
-
Acute Disease
-
Adult
-
Angioplasty, Balloon, Coronary / adverse effects*
-
Angioplasty, Balloon, Coronary / methods
-
Antibodies, Monoclonal / adverse effects*
-
Anticoagulants / adverse effects
-
Coronary Angiography
-
Coronary Thrombosis / diagnostic imaging*
-
Coronary Thrombosis / etiology*
-
Coronary Thrombosis / therapy
-
Heparin / adverse effects*
-
Humans
-
Immunoglobulin Fab Fragments / adverse effects*
-
Male
-
Myocardial Infarction / therapy
-
Platelet Aggregation Inhibitors / adverse effects
-
Stents / adverse effects*
-
Thrombocytopenia / chemically induced
-
Thrombocytopenia / complications*
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Anticoagulants
-
Immunoglobulin Fab Fragments
-
Platelet Aggregation Inhibitors
-
Heparin
-
Abciximab